Lipoprotein Lipase Binds to Low Density Lipoprotein Receptors and Induces Receptor-mediated Catabolism of Very Low Density Lipoproteins
Open accessAbstract
Lipoprotein lipase (LPL), the major enzyme responsible for the hydrolysis of plasma triglycerides, promotes binding and catabolism of triglyceride-rich lipoproteins by various cultured cells. Recent studies demonstrate that LPL binds to three members of the low density lipoprotein (LDL) receptor family, including the LDL receptor-related protein (LRP), GP330/LRP-2, and very low density lipoprotein (VLDL) receptors and induces receptor-mediated lipoprotein catabolism. We show here that LDL receptors also bind LPL and mediate LPL-dependent catabolism of large VLDL with Sf 100-400. Up-regulation of LDL receptors by lovastatin treatment of normal human foreskin fibroblasts (FSF cells) resulted in an increase in LPL-induced VLDL binding and catabolism to a level that was 10-15-fold greater than in LDL receptor-negative fibroblasts, despite similar LRP activity in both cell lines. This indicates that the contribution of LRP to LPL-dependent degradation of VLDL is small when LDL receptors are maximally up-regulated. Furthermore studies in LRP-deficient murine embryonic fibroblasts showed that the level of LPL-dependent degradation of VLDL was similar to that in normal murine embryonic fibroblasts. LPL also promoted the internalization of protein-free triglyceride emulsions; lovastatin-treatment resulted in 2-fold higher uptake in FSF cells, indicating that LPL itself could bind to LDL receptors. However, the lower induction of emulsion catabolism as compared with native VLDL suggests that LPL-induced catabolism via LDL receptors is only partially dependent on receptor binding by LPL and instead is primarily due to activation of apolipoproteins such as apoE. A fusion protein between glutathione S-transferase and the catalytically inactive carboxyl-terminal domain of LPL (GST-LPLC) also induced binding and catabolism of VLDL. However GST-LPLC was not as active as native LPL, indicating that lipolysis is required for a maximal LPL effect. Mutations of critical tryptophan residues in GST-LPLC that abolished binding to VLDL converted the protein to an inhibitor of lipoprotein binding to LDL receptors. In solid-phase assays using immobilized receptors, LDL receptors bound to LPL in a dose-dependent manner. Both LPL and GST-LPLC promoted binding of VLDL to LDL receptor-coated wells. These results indicate that LPL binds to LDL receptors and suggest that the carboxyl-terminal domain of LPL contributes to this interaction.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increased levels of plasma LPL following gene transfer may promote lipoprotein clearance both by increasing the rate of lipolysis and exposing the receptor-binding domain of apoE, as well as by direct receptor-mediated clearance mechanisms involving LPL.
“The increased levels of plasma LPL following gene transfer may promote lipoprotein clearance both by increasing the rate of lipolysis and exposing the receptor-binding domain of apoE, as well as by direct receptor-mediated clearance mechanisms involving LPL ( 38,39 ).”
From Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4 (2011) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 5
- Beisiegel, U., Weber, W., and Bengtsson-Olivecrona, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346
- Jaffe, E. A. (1980) Transplant. Proc. 12, 49 -53
- Takahashi, S., Kawarabayasi, Y., Nakai, T., Sakai, J., and Yamamoto, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9252-9256
- Herz, J., Qui, S-Q., Oesterle, A., DeSilva, H. V., Shafi, S., and Havel, R. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4611-4615
- Willnow, T. E., Armstrong, S. A., Hammer, R. A., and Herz, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4537-4541
Cited by
Sorted by citations
Lipoprotein Lipase in the Brain and Nervous System
Wang, H., & Eckel, R. H. (2012) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071811-150703 · Cited by 105 · see citing works
D. Bruce, K., Tang, M., Reigan, P., & H. Eckel, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218338 · Cited by 36 · see citing works
Vezeridis, A. M., Drosatos, K., & Zannis, V. I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m008409 · Cited by 11 · see citing works
Fotakis, P., Vezeridis, A., Dafnis, I., Chroni, A., Kardassis, D., & Zannis, V. I. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m048348 · Cited by 4 · see citing works
- Authors
- Medh, J. D., Bowen, S. L., Fry, G. L., Ruben, S., Andracki, M., Inoue, I., Lalouel, J.-M., Strickland, D. K., & Chappell, D. A.
- Affiliations
- University of Iowa (US)
- University of Utah (US)
- American Red Cross (US)
- Corresponding author
- Medh, Jheem D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-07
- Volume
- 271
- Issue
- 29
- Pages
- 17073-17080
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2129205716
- Cited by
- 89
- References
- 0
- Citations by year
- 2026: 2 · 2023: 1 · 2020: 2 · 2019: 3 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 2
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL49264, P01HL049264)
- National Institute of General Medical Sciences (R01GM042581, GM-42581)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- lipoprotein lipase, LDL receptor, LDL receptor-related protein, lovastatin, apolipoprotein E, lipolysis, lipoprotein binding, tryptophan residues, lipoprotein metabolism, fibroblasts
- MeSH terms
- Alanine, Binding Sites, Catalysis, Cells, Cultured, Emulsions, Fat Emulsions, Intravenous, Fibroblasts, Glutathione Transferase, Humans, Kinetics, Lipoprotein Lipase, Lipoproteins, VLDL, Male, Receptors, LDL, Recombinant Fusion Proteins, Skin, Tryptophan, Mutagenesis, Site-Directed, Point Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review